Browsing Category
Pharma Industry News
4729 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
What’s driving GH Research’s stock spike? FDA IND verdict looms for lead depression candidate
GH Research is set to update investors on its FDA IND filing and Phase 3 launch plans for GH001. Find out what this means for its future in depression treatment.
AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease
AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025.
Vanda Pharmaceuticals (NASDAQ: VNDA) wins long-awaited FDA approval for NEREUS, first new motion sickness drug in 40+ years
Find out how Vanda Pharmaceuticals’ FDA-approved NEREUS (tradipitant) is redefining motion sickness treatment after 40 years of stagnation. Read the full story now.
Halda Therapeutics joins Johnson & Johnson in $3bn cancer drug platform deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B. Find out why its RIPTAC platform could reshape prostate and solid tumor cancer treatment.
Gilead Sciences acquires RP-3467 from Repare Therapeutics to strengthen synthetic lethality pipeline
Gilead buys RP-3467 from Repare for up to $30M, boosting Repare’s shareholder payout ahead of its Xeno acquisition. Find out what this means for oncology.
Mabwell begins first-in-class Phase II trial of IL-11 antibody 9MW3811 for scarring in China
Mabwell dosed the first patient in its Phase II trial for IL-11 antibody 9MW3811, targeting pathological scarring. Find out what makes this a global first.
Mabwell’s adalimumab biosimilar wins BPOM nod: Is Southeast Asia becoming the next battleground for biosimilars?
Mabwell’s adalimumab biosimilar wins approval in Indonesia. Find out what this means for Southeast Asia’s biologics market and Mabwell’s global ambitions.
Corcept Therapeutics (NASDAQ: CORT) plunges as FDA rejects relacorilant for Cushing’s-related hypertension therapy
Corcept shares nosedive after FDA rejection of relacorilant for Cushing’s syndrome-related hypertension. Find out what this means for the company’s future.
China just sided with Novo Nordisk—here’s why this Wegovy patent ruling matters worldwide
China’s top court just backed Novo Nordisk’s semaglutide patent—find out what this means for Wegovy and obesity drug rivals in 2026 and beyond.
Cogent Biosciences (NASDAQ: COGT) slips after hours as insider sales prompt investor scrutiny
Cogent Biosciences stock fell after hours on insider sales by multiple executives. Find out why it matters now and what it means for investors going forward.